Cargando…

Management of a High-Risk Surgery with Emicizumab and Factor VIII in a Child with a Severe Hemophilia A and Inhibitor

Detalles Bibliográficos
Autores principales:	Lefèvre, Charles R., Jaffré, Anaïs, Pontis, Adeline, Nedelec-Gac, Fabienne, Guéret, Pierre, Gouin-Thibault, Isabelle, Fraisse, Bernard, Bayart, Sophie, Guillet, Benoit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116169/ https://www.ncbi.nlm.nih.gov/pubmed/34007955 http://dx.doi.org/10.1055/s-0041-1728667

Ejemplares similares

A performance evaluation of sthemO 301 coagulation analyzer and associated reagents
por: Pontis, Adeline, et al.
Publicado: (2023)

Impact of age on in vitro metabolism of clopidogrel: a potential explanation for high on-treatment platelet reactivity in the elderly?
por: Pontis, Adeline, et al.
Publicado: (2022)

Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
por: Schmitt, Christophe, et al.
Publicado: (2021)

Platelet Functions During Extracorporeal Membrane Oxygenation. Platelet–Leukocyte Aggregates Analyzed by Flow Cytometry as a Promising Tool to Monitor Platelet Activation
por: Mansour, Alexandre, et al.
Publicado: (2020)

Verification and Comparison of Chromogenic Factor VIII Activity Assays in Patients With Hemophilia Treated With and Without Emicizumab
por: Lee, Min Young, et al.
Publicado: (2023)

Emicizumab Associated Rhabdomyolysis in Hemophilia A
por: Wilson, Joseph A., et al.
Publicado: (2020)

Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy
por: Hatayama, Yuki, et al.
Publicado: (2022)

Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
por: Jonsson, Fredrik, et al.
Publicado: (2021)

Utilization of Emicizumab in Acquired Factor VIII Deficiency
por: Hess, Kevin J., et al.
Publicado: (2020)

P1616: EMICIZUMAB FOR THE MANAGEMENT OF ACQUIRED HEMOPHILIA A
por: Sridharan, Meera, et al.
Publicado: (2023)

Traumatic Tonsillar Hemorrhage during Hemophilia A Treatment with Emicizumab
por: Inoue, Fumiya, et al.
Publicado: (2022)

Management of children with hemophilia A on emicizumab who need surgery
por: Belletrutti, Mark, et al.
Publicado: (2023)

Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis
por: Garcia, Jessica, et al.
Publicado: (2023)

Disruptive technology and hemophilia care: The multiple impacts of emicizumab
por: Hermans, Cedric, et al.
Publicado: (2021)

Emicizumab Use in Treatment of Acquired Hemophilia A: A Case Report
por: Al-Banaa, Kadhim, et al.
Publicado: (2019)

Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations
por: Yada, Koji, et al.
Publicado: (2019)

Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A
por: Le Quellec, Sandra
Publicado: (2020)

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database
por: Peyvandi, Flora, et al.
Publicado: (2020)

Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective
por: Camelo, Ricardo Mesquita, et al.
Publicado: (2023)

The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study
por: Schultz, Nina Haagenrud, et al.
Publicado: (2021)

Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)
por: Jiménez‐Yuste, Víctor, et al.
Publicado: (2022)

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A
por: Gelbenegger, Georg, et al.
Publicado: (2020)

Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2021)

Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
por: Albattat, Sami, et al.
Publicado: (2023)

Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center
por: Cohen, Omri, et al.
Publicado: (2023)

Emicizumab prophylaxis in a Korean child with severe hemophilia A and high titer inhibitor: a case report
por: Ahn, Ji Hyun, et al.
Publicado: (2021)

PB2647: USE OF EMICIZUMAB FOR THE TREATMENT OF ACQUIRED HEMOPHILIA A: A SYSTEMATIC REVIEW
por: Al-Housni, Zainab, et al.
Publicado: (2023)

Absence of Effect of Emicizumab on D-Dimer Concentrations in Adult Patients with Severe Hemophilia A
por: Iarossi, Michael, et al.
Publicado: (2022)

Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A
por: Zhou, Zheng-Yi, et al.
Publicado: (2020)

Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)
por: Yang, Renchi, et al.
Publicado: (2022)

Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study
por: Donners, Anouk A. M. T., et al.
Publicado: (2022)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single‐center report
por: Warren, Beth Boulden, et al.
Publicado: (2021)

Non-inhibitory antibodies inducing increased emicizumab clearance in a severe hemophilia A inhibitor patient
por: Harroche, Annie, et al.
Publicado: (2021)

Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience
por: Rener, Karla, et al.
Publicado: (2023)

Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
por: Liu, Guoqing, et al.
Publicado: (2022)

PB2643: EFFICACY OF REDUCED-DOSE EMICIZUMAB IN HEMOPHILIA A WITH INHIBITORS: REAL WORLD EXPERIENCE IN MALAYSIA
por: Tang, Andy Sing Ong, et al.
Publicado: (2023)

Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays
por: Kizilocak, Hande, et al.
Publicado: (2019)

Successful Perioperative Combination of High-Dose FVIII Therapy Followed by Emicizumab in a Patient with Hemophilia A with Inhibitors
por: Okamoto, Shuichi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_aj52neuvuea7a9frhqrsie60ne